What The Study Did: Researchers evaluated whether receiving by injection the monoclonal antibodies casirivimab and imdevimab was associated with reduced hospitalization and death compared with nontreatment among patients with COVID-19 and whether outcomes were similar if administered by injection or intravenously. Administration by injection could expand outpatient treatment capacity but its effectiveness is unknown.
Authors: Erin K. McCreary, Pharm.D., of the University of Pittsburgh School of Medicine, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.6920)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.6920?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041222
About JAMA Network Open : JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open